Company intelligence / Profile preview
Allife Medicine
Beijing, Beijing Shi, Chinahpscreg.eu ↗
- Ownership
- Private
- Employees
- ~190
- Development stage
- Phase 1
01
Overview
Allife Medicine is a leading Chinese biotech specializing in iPSC-based cell therapies, with first-in-China clinical approvals for both CAR-NK cell injection targeting ovarian cancer and iPSC-derived endothelial progenitor cells for acute ischemic stroke. The company has multiple programs in Phase 1 trials, a robust patent portfolio, and significant R&D capacity.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Induced pluripotent stem cells (iPSC)Cell therapyGene therapyCAR-NK cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Allife Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allife Medicine.